Acesso livre
Acesso livre

Terapia Intensiva

Retrospectiva: principais artigos de 2021 sobre doenças infecciosas além da COVID.

17 Dez, 2021 | 12:06h

Year In Review: Top Non-COVID Infectious Diseases Articles Of 2021 – IDStewardship

 

Comentário no Twitter

 

Medicamento da Merck contra COVID perde seu brilho: o que isso significa para a pandemia – “Molnupiravir foi inicialmente anunciado pelos oficiais de saúde pública como um elemento que mudaria o cenário da COVID-19, mas dados finais dos estudos clínicos mostraram eficácia abaixo das expectativas.”

16 Dez, 2021 | 13:04h

Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature

Conteúdos relacionados:

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Recomendações para a seleção de antibióticos em infecções nosocomiais graves.

16 Dez, 2021 | 12:55h

Recommendations for antibiotic selection for severe nosocomial infections – Revista Espanola de Quimioterapia

Guia para nutrição enteral em unidades de terapia intensiva: 10 dicas de especialistas para a prática clínica.

16 Dez, 2021 | 12:45h

A guide to enteral nutrition in intensive care units: 10 expert tips for the daily practice – Critical Care

Revisão | Impacto da obesidade na doença grave.

16 Dez, 2021 | 12:44h

Impact of Obesity in Critical Illness – CHEST

Aprendizado sobre doenças infecciosas a partir de pacientes internados por tais doenças.

15 Dez, 2021 | 12:23h

ID Learning Units from Inpatient ID Consults – HIV and ID Observations

Podcast | Zero tensão para a hipertensão do paciente internado.

14 Dez, 2021 | 15:58h

#310 No Tension About Inpatient Hypertension with Dr. Noble Maleque – The Curbsiders

COVID-19 e trombose: busca por evidências.

13 Dez, 2021 | 11:35h

COVID-19 and thrombosis: searching for evidence – Hematology, ASH Education Program

Como reconhecer e tratar a coagulopatia associada a COVID-19.

13 Dez, 2021 | 11:34h

How to recognize and manage COVID-19-associated coagulopathy – Hematology, ASH Education Program

M-A | Diltiazem vs. metoprolol intravenosos para fibrilação atrial com frequência ventricular rápida.

10 Dez, 2021 | 11:08h

Intravenous diltiazem versus metoprolol for atrial fibrillation with rapid ventricular rate: A meta-analysis – The American Journal of Emergency Medicine (link para o resumo – $ para o texto completo)

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.